CP007

HAEMATOLOGICAL SIDE EFFECTS OF TELAPREVIR-BASED TRIPLE THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C MONOINFECTION

A.M. Fernández Ruiz-Moron[1], R. Manzano Lorenzo[1], S. Hernández Tapias[1], V. Puebla Garcia[1], M.T. Benítez Jimenez[1], M.L. Arias Fernandez[1].
[1]Hospital Clínico San Carlos, Pharmacy, Madrid, Spain
Correspondence to Ana Fernández Ruiz-Morón: afruizmoron@salud.madrid.org

OBJETIVES

To discuss the hematological side effects of telaprevir, ribavirin and interferon, in patients with chronical hepatitis C genotype 1.

MATERIALS AND METHODS

Retrospective, observational study
Initiated the treatment during 2012 and have at least 3 months of treatment.
Analyzed: dispensing records of medication and the values of hemoglobin, lymphocytes and platelets

RESULTS

53 patients were included, 36 men and 17 women. The average age was 56 years (max. 73; min 40).
In 52,9% of patients, the Hb value was under 10 g/dl
The baseline level, the lowest average level of Hb , limphocytes and platelets, and the day that it was reached are shown in the table.

	BASELINE	LOWEST VALUE	DAY
HB	15,2 g/dl	9,9 g/dl	81
LIMPHOCYTES	2,1 x10^3/µl (max. 4,3; min 0,7 x10^3/µl)	0,83x10^3/µl (max. 1,8; min 0,2 x10^3/µl)	89
PLATELETS	160,85 x10^3/µl (max.317; min 61 x10^3/µl	84,8 x10^3/µl (max. 253; min 24 x10^3/µl)	82

The grades of anemia and thrombocytopenia of the included patients are:

Anemia grade	Number of patients	Thrombocytopenia grade	Number of patients
Mild	12	2	26
Moderate	14	3	10
Severe	2	4	1

CONCLUSIONS

The reduction of the hematological parameters in patients treated with triple therapy occurred around one month after initiating the treatment, reaching the lowest levels after 12-16 weeks, coinciding approximately with the end of the protease inhibitor treatment. This fits our expectations concerning to the studies